Bacterial infection has been considered one of the primary
reasons
for low survival rate of lung cancer patients. Herein, we demonstrated
that a kind of mesoporous silica nanoparticles loaded with anticancer
drug doxorubicin (DOX) and antimicrobial peptide HHC36 (AMP) (MSN@DOX-AMP)
can kill both commensal bacteria and tumor cells under GSH-triggering,
modulating the immunosuppressive tumor microenvironment, significantly
treating commensal bacterial infection, and eliminating in
situ lung tumors in a commensal model. Meanwhile, MSN@DOX-AMP
encapsulated DOX and AMP highly efficiently via a
combined strategy of physical adsorption and click chemistry and exhibited
excellent hemocompatibility and biocompatibility. Importantly, MSN@DOX-AMP
could be inhaled and accumulate in lung by a needle-free nebulization,
achieving a better therapeutic effect. This system is expected to
serve as a straightforward platform to treat commensal bacterial infections
in tumors and promote the translation of such inhaled GSH-triggered
MSN@DOX-AMP to clinical treatments of lung cancer.